Podcasts about merck sharp

To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad-spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injuryMultiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order. 

To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad-spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injuryMultiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary formsLevagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

Comment les rhumatologues peuvent-ils gérer la prescription d'un vaccin en tenant compte des traitements immunosuppresseurs ? Quel est le délai recommandé pour vacciner un patient ayant récemment contracté une infection, et pourquoi ? Quels sont les conseils pour motiver les patients qui hésitent ou ont des inquiétudes face aux vaccins ? Comment adapter les recommandations vaccinales en fonction des spécificités des patients en rhumatologie ? Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

Quelles sont les raisons principales pour lesquelles les rhumatologues doivent s'intéresser à la vaccination ? Quels sont les nouveaux vaccins susceptibles d'avoir un impact sur les patients suivis en rhumatologie ? Quelles avancées récentes marquent l'actualité dans le domaine des vaccinations ?  Le Professeur Jacques Morel, rhumatologue au CHU de Montpellier et responsable du centre de référence des maladies auto-immunes, nous éclaire à ce sujet. Notre invité déclare avoir des liens d'intérêt avec : Bristol Myers Squibb, Celltrion, Lilly, Novartis, Pfizer, Sanofi, Merck Sharp and Dohme, Abbvie, Fresenius Kabi, Mylan, Boehringer Ingelheim, Galapagos, Glaxo Smith Kline, Roche, Union Chimique Belge, Janssen, Medac, Sandoz, Nordic Pharma. L'équipe : Comité scientifique :  Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Biotherapeutics' CEO, Fred Aslan, M.D.The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company's cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva's pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad-spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.PEA was first discovered in 1957 by scientists at Merck Sharp & Dome, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injuryMultiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves. Learn more about Emerald Labs PEA+ LevagenUse the code: Forever and get 20% off your order.

- Chúng ta sẽ thế nào ở 10-20 năm sau, nếu không bắt đầu yêu thương và chăm sóc bản thân từ hiện tại? Đó chính là vấn đề được đặt ra qua Triển lãm AI phòng vệ HPV, do Hội Y học dự phòng Việt Nam và Công ty Dược phẩm đa quốc gia Merck Sharp & Dohme (MSD) phối hợp thực hiện. Chương trình diễn ra trong 3 ngày, từ 18-20/10 tại Phố đi bộ Nguyễn Huệ, TP.HCM. Chủ đề : AI, HPV --- Support this podcast: https://podcasters.spotify.com/pod/show/vov1tintuc/support

Pharmaceutical company Merck & Co., Inc. (Merck) filed a lawsuit against the U.S. Department of Health and Human Services (HHS) challenging the Medicare drug price negotiation program established by the Inflation Reduction Act of 2022. Merck argues that the drug pricing program violates the First Amendment and the Takings Clause of the Fifth Amendment, claiming it forces them to accept government-dictated prices and infringes on their property rights. The federal government, represented by HHS Secretary Xavier Becerra and others, contends that Merck's arguments are unfounded and that the negotiation program is essential for reducing drug costs and ensuring the financial stability of Medicare. The case could significantly impact drug pricing, Medicare costs, and federal regulatory authority in healthcare.The case was filed on June 6, 2023, in the U.S. District Court for the District of Columbia. On October 19, 2023, Merck filed an amended complaint adding its subsidiary Merck Sharp & Dohme LLC as a second plaintiff. The case is ongoing, with both parties having filed motions for summary judgment.Join us for a litigation update on Merck et al. v. Becerra et al. with Yaakov M. Roth, one of the lead attorneys at Jones Day representing Merck & Co., Inc.

On this special episode offering CPE Credits, Fred Goldstein Invites Susan Wojcicki Roman, clinical pharmacy lead at Humana Pharmacy Solutions to discuss Breaking Biases in Breast Cancer. This activity is supported by an independent medical education grant from Novartis Pharmaceuticals Corporation and Merck Sharp and Dohme. AMCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Full instructions on how to claim CPE credits can be found here (https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:cce0dc42-2b1b-4e42-8543-d1c93730e81d) Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

On this special episode offering CPE Credits, Fred Goldstein Invites Danielle Roman, manager of clinical pharmacy services at Allegheny Health Network Cancer Institute to discuss Breast Cancer Breakthroughs: A Peek into the Pipeline. This activity is supported by an independent medical education grant from Novartis Pharmaceuticals Corporation and Merck Sharp and Dohme. AMCP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Full instructions on how to claim CPE credits can be found here (https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:cce0dc42-2b1b-4e42-8543-d1c93730e81d) Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Tercera hora de Visión Global en Radio Intereconomía que empezamos con nuestro consultorio de Wall Street en el que nos acompaña Juan Ignacio Marrón, analista independiente y fundador de @InversoresInstitucionales. Con él analizamos compañías como Carvana, Advanced Micro Devices, Paypal, Bavarian Nordic, AMC Entertainment Holdings, Intuitive Surgical, ASML Holding, Broadcom, SuperMicro, Merck Sharp and Dohme, Mercedes-Benz Group, Hershey Company, General Motors. Después, último vistazo a los mercados y repasamos titulares empresariales con Estefanía Muniz y María de la Cerca. Habalmos del FROB, la sanción a la SGAE, Endesa, Solarpack y Shell. Terminamos con el análisis en el que nos acompaña Samuel Abraldes, CEO de Socaire. Con él, analizamos y hacemos balance de la jornada en los mercados en un día marcado por la indefinición en los índices de Wall Street.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan. For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠. Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Shehla Shaikh Dr. Shaikh declares no current financial conflict of interest Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease. For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Darren K. McGuire Clinical trial leadership: - Former: Esperion, AstraZeneca, CSL Behring - Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam Consultancy: - Former: Merck & Co - Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-making in type 2 diabetes care. For more free education, go to ⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠@dkipractice⁠⁠⁠) or connect on ⁠⁠LinkedIn⁠⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Alice Cheng Advisory Board: Abbott, AstraZeneca, Bayer Speakers Bureau: Abbott, Amgen, AstraZeneca, Bausch, Bayer Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠⁠) or connect on ⁠LinkedIn⁠⁠. Faculty disclosures Prof. Francesco Giorgino Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Erika Bezerra Parente Honoraria for lectures, presentations and education events: Sanofi Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: None

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This week, we speak to Artiva Biotherapeutics' CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company's cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles.Artiva's pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. 

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well. For more free education, go to diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice⁠) or connect on LinkedIn⁠. Disclosures Prof. Francisco Giorgino: Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Vanita Aroda: Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi Target Audience: Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists Geographic: Global (ex US and UK audiences) Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 2023) congress. The congress featured over 200 scientific sessions and symposia, and 1,400 posters. Among the topics discussed are trials investigating therapies to treat obesity in patients with type 2 diabetes (T2D), as well as discussion about remission and what it really means for T2D. For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠) or connect on ⁠LinkedIn⁠. Disclosures Prof. Francisco Giorgino: Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Richard E. Pratley Research grant: Dompe, Novo Nordisk Honoraria for lectures, presentations and education events: Merck, Novo Nordisk Consulting: Bayer AG, Endogenex Inc., Gasherbrum Bio Inc., Henguri (USA) Ltd. Intas Pharmaceuticals Inc. Eli Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., Sun Pharmaceutical Industries Target Audience: Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists Geographic: Global (ex US and UK audiences) Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Check out the latest episode of the CUES Podcast, "Becoming a CEO With a Vision for Technology and Teamwork," with guest Dana DeFilippis, CCE, CEO of Merck Sharp & Dohme Federal Credit Union. Now CEO at the credit union for two years, DeFilippis has leveraged the knowledge she gathered to help her use technology and teamwork to promote staff innovation and better serve members.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/decoding-and-discussing-pah-guidelines-8896Featuring faculty Ioana Preston, MD, moderated by Corinne R. Young, MSN, FNP-C, FCCPSummaryIn this episode of NACE Clinical Highlights, Dr. Ioana Preston joins NP Corinne Young to discuss the diagnosis and treatment of pulmonary arterial hypertension (PAH). They dive into the importance of ruling out other groups of pulmonary hypertension and highlight the role of VQ scans in diagnosing chronic clots. The significance of right heart catheterization in confirming the diagnosis and guiding treatment decisions is emphasized. The discussion also covers risk stratification and the benefits of dual upfront therapy with oral drugs for most group one PAH patients, as well as risk stratification-based follow-up management. Finally, Dr. Preston provides insights into upcoming advancements in therapeutic options.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify patients with PAH, utilizing updated definitions and diagnostic evaluationsInitiate therapy for patients with PAH based on currently available guidelinesTransition between therapies in patients with PAH based on risk stratification and guideline- and goal-directed therapyThis activity is accredited for CME/CE Credit.Provided by the National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresDr. Preston has disclosed the following financial relationships:Consultant: Aerovate, Altavant, Gossamer, Janssen, Liquidia, Merck, Respira, United TherapeuticsAdvisor: Aerovate, Altavant, Gossamer, Janssen, Liquidia, Merck, Respira, United TherapeuticsContracted Research: Janssen, Merck, United TherapeuticsAll her disclosures are related to pulmonary hypertension.Ms. Young has disclosed the following financial relationships:Advisor: AstraZeneca (Asthma), Takeda (Alpha1)Speaker: Griffols (AAT)AAT: alpha-1 antitrypsinAll of the relevant financial relationships listed for these individuals have been mitigated.Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis presentation is supported by an educational grant from Merck Sharp & Dohme Corp.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Hosts Gil Bashe and Gregg Masters welcome Dr. Junaid Bajwa, Chief Medical Scientist at Microsoft Research and a practicing physician in the NHS (the UK's National Health Service). Dr. Bajwa was previously the Global Lead for Strategic Alliances and Solutions for the Global Digital Centre of Excellence at Merck Sharp & Dohme. He cofounded “VelocityHealth”, Europe's first prevention focused digital-health accelerator, in partnership with Telefonica, and led his team to deliver the “NHS Testbed” in partnership with Verily Life Sciences (part of Alphabet), which the Health Service Journal recognized as the “Best Pharmaceutical Partnership with the NHS” in 2018. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio.” Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

James Gallagher asks whether a weight-loss drug on the NHS heralds a new era in tackling obesity? He meets Jan who lost nearly 4 stone after being part of a trial taking a weekly injection of Semaglutide for 15 months alongside advice on meals and exercise. However, when people stop taking the drug the weight starts to go back on. Add to that supply shortages with heightened private demand and some doctors think the drug is as controversial as they come. James unpicks the ethical and societal dilemmas against a backdrop of half the world's population projected to be overweight or obese by 2035. Producer: Erika Wright Declared interests Dr Margaret McCartney: "No conflicts to declare." Prof Sir Stephen O'Rahilly : "in the past has been a remunerated consultant and has had research collaboration with Novo Nordisk." Professor Naveed Sattar: "consulted for and/or received speaker honoraria from Novo Nordisk, Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, and Sanofi; and grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics. He was a co-investigator in lifestyle trials such as DiRECT and co-lead for STANDby."

Se por um lado a pandemia de Covid-19 impulsionou um enorme crescimento da vacinação, por outro também mostrou que o calendário de vacinação de adultos e crianças anda sendo negligenciado. Segundo dados da Merck Sharp & Dohme (MSD), as proteções mais procuradas pelos brasileiros são contra Covid-19, poliomielite, doenças pneumocócicas e Influenza - juntas somam mais de 80 milhões de doses, ou metade de todo o mercado de vacinação brasileiro. Até junho do ano passado, o país tinha registrado uma redução de 12,7% nas aplicações de vacinas gerais, quando comparado com o mesmo período de 2021. Para explicar melhor esse cenário, vamos conversar com a Dra. Juliana Oliveira da Silva, infectologista coordenadora do Centro de Vacinação do Hcor (Hospital do Coração)

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Prof. Naveed Sattar declares the following financial relationships from the past 24 months: Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Educational Objectives ·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens ·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC   Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of Pharmacy Minnesota Oncology St. Paul, Minnesota   Latha Radhakrishnan, PharmD, BCOP Clinical Oncology Pharmacist The University of Illinois Hospital and Health Sciences System Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Chicago, Illinois   Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Epizyme Speakers Bureau: AstraZeneca   Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Taiho, Novartis, Exelixis Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis   Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta. Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens ·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC   Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of Pharmacy Minnesota Oncology St. Paul, Minnesota   Latha Radhakrishnan, PharmD, BCOP Clinical Oncology Pharmacist The University of Illinois Hospital and Health Sciences System Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Chicago, Illinois   Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Epizyme Speakers Bureau: AstraZeneca   Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Taiho, Novartis, Exelixis Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis   Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta. Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.  https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives ·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens ·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC   Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of Pharmacy Minnesota Oncology St. Paul, Minnesota   Latha Radhakrishnan, PharmD, BCOP Clinical Oncology Pharmacist The University of Illinois Hospital and Health Sciences System Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Chicago, Illinois   Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Epizyme Speakers Bureau: AstraZeneca   Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Taiho, Novartis, Exelixis Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis   Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta. Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.  https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations Learn more about your ad choices. Visit megaphone.fm/adchoices

 20/01/2022. Адміністрація терапевтичних товарів (TGA) надає дозвіл на вакцину Novavax та попередньо схвалює два пероральних противірусних методи лікування COVID-19. Нові ліки Merck Sharp and Dohme's, Paxlovid,  Pfizer's Lagevrio  прибудуть до Австралії незадовго, але вони не замінятимуть вакцинування. Тенісний турнір у Мельбурні та ковідні перипетії. Про це та більше на хвиялх SBS Ukrainian...

Today we're joined by Professor Naveed Sattar for a summary of some of the key takeaways from the International Diabetes Federation Virtual Congress 2021. Professor Sattar is Professor of Metabolic Medicine at the University of Glasgow, and was Committee Lead for the Cardiovascular Disease & Hypertension stream at the congress. For more free education, go to diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Naveed Sattar declares the following: Advisory board: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Institutional research grant: Boehringer Ingelheim All conflicts have been mitigated prior to this activity. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Mr. Temitayo (Tayo) Erogbogbo, is Global Advocacy Director of MSD for Mothers (https://www.msdformothers.com/), at Merck Sharp & Dohme. Tayo has two decades of combined private sector and international development experience, 13 years of which was spent in the pharmaceutical industry in multiple roles across community relations, government affairs, marketing and sales. As the Global Advocacy Director of MSD for Mothers, Tayo is responsible for global and national strategic partnerships and programs to bring about policies and practice changes to improve maternal health care, and strengthen health systems, particularly where private sector approaches can be leveraged for greater impact. Prior to MSD for Mothers, Tayo led the establishment of an adolescents and youth constituency at The Partnership for Maternal, Newborn and Child Health (PMNCH), a multi-constituency partnership hosted by the World Health Organization, to advocate for better sexual, reproductive, maternal, newborn, child, and adolescent health policies and services at global, regional, and national levels. Additionally, he contributed to the development of the Global Strategy for Women's, Children's, and Adolescents' Health 2016-2030. Previously, in collaboration with multi-sectoral partners in Nigeria, he contributed to the passage of the National Health Bill, the development of the National Gender Policy Guidelines and the passage of Violence Against Person's Prohibition in support of gender equality. Tayo also spearheaded Abbott's HIV patient relations function within Europe, developing services to support people living with HIV by partnering with community organizations. He advocated for anti-retroviral drug access across Africa and developed a health care professional (HCP) train-the-trainer program that has educated over 3,000 HCPs. Tayo earned a BSc in Management Sciences from Loughborough University, and a MSc in Information Technology for Management from Coventry University. Tayo is also an elite athlete in the Triple Jump with a Bronze medal at the European U23 Championships.

最近由德國藥廠 Merck Sharp & Dohme 研發的新冠口服劑 Molnupiravir 廣受世界注目。究竟這隻口服劑是一種怎麽樣的藥物？它如何發揮對抗新冠病毒的功能？

Entrevista de Carlos Mira en Mira quién Habla a Gabriela Bugarin, medica infectologa en Merck, Sharp & Dohme, porque empresa farmacéutica Merck Sharp & Dohme (MSD) anunció que su píldora experimental COVID-19 redujo a la mitad las hospitalizaciones y muertes en personas recientemente infectadas por el coronavirus.

In another news episode, hear a 5-minute summary of the VERTIS CV post hoc analysis presented at ESC 2021. VERTIS CV was the the cardiovascular outcomes trial investigating the SGLT2 inhibitor ertugliflozin in people with type 2 diabetes and cardiovascular disease; this latest analysis looked at whether the effects of ertugliflozin on cardiovascular and renal outcomes varied according to baseline metformin use. Listen for a quick overview of the key findings. Abstract: Cosentino F, et al. Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial. Eur Heart J 2021. In press For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

In the last episode of series 3, we're joined by Anne Peters, Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California, USA, to discuss recent data on potential new therapies in development, and what this might mean in the future. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References Rosenstock J, et al. Lancet. 2021 Jun 25;S0140-6736(21)01324-6 [SURPASS-1]. Frias J P, et al. N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519. Online ahead of print [SURPASS-2] Abstract 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3) Abstract 80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5) Bhatt D L, et al. Late-Breaking Clinical Trials IV. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting). Disclosures: Prof. Anne Peters declares the following: Participation on an advisory board: Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, Zealand Research Support: Dexcom, Insulet and donated devices from Abbott Diabetes Care Stock Options: Omada Health, Teladoc All conflicts of interest have been mitigated prior to this activity. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Another special episode looking at an in-depth case study, this time regarding use of GLP-1 receptor agonists. Joining us to discuss the case is Dr Deborah Wexler, Associate Professor of Medicine at Harvard Medical School, Boston MA, USA, who was a co-author of the ADA-EASD Consensus Statement on Management of Hyperglycemia in Type 2 Diabetes. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Dr Deborah Wexler declares the following: Member of data monitoring committee for SOUL and FLOW trials studying semaglutide, a GLP-1 receptor agonist: Novo Nordisk All conflicts of interest have been mitigated prior to this activity. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

This episode brings together much of what we have discussed so far regarding use of SLGT2 inhibitors. We're joined for a case discussion by Professor Francesco Giorgino, who is Professor of Endocrinology at the University of Bari Aldo Moro in Italy, where he is also Chief of the Division of Endocrinology at the university hospital, and President of the Italian Society of Endocrinology. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Dr Professor Francesco Giorgino declares the following: Grants/Research Support recipient: Eli Lilly, Roche Diabetes Care Consultant (Occasional): Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, Sanofi Honorarium recipient: Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, AstraZeneca, Sanofi, Mundipharma All conflicts of interest have been mitigated prior to this activity. Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

This year's Scientific Sessions of the American Diabetes Association was the second in a row to be held virtually. Nevertheless, the conference was still packed with the usual informative symposia and original research we would expect from ADA. We spoke to three of the speakers to discuss the highlights, including: - Professor Anne Peters on STEP, SUSTAIN FORTE and AMPLITUDE-O - Dr Deborah Wexler on GRADE - Professor Francesco Giorgino on the SURPASS programme For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References - The Management of Type 1 Diabetes in Adults — A Consensus Report by the ADA and EASD (draft) - Abstract 101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial - Wilding J, et al. N Engl J Med. 2021 Mar 18;384(11):989 [STEP 1]. - UK Prospective Diabetes Study - Nathan D, et al. Diabetes Care 2013 Aug; 36(8): 2254-2261 [GRADE]. - Rosenstock J, et al. Lancet. 2021 Jun 25;S0140-6736(21)01324-6 [SURPASS-1]. - Frias J P, et al. N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519. Online ahead of print [SURPASS-2] - Abstract 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3) - Abstract 80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5) Disclosures: Prof. Anne Peters declares the following: Participation on an advisory board: Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, Zealand Research Support: Dexcom, Insulet and donated devices from Abbott Diabetes Care Stock Options: Omada Health, Teladoc Dr Deborah Wexler declares the following: Member of data monitoring committee for SOUL and FLOW trials studying semaglutide, a GLP_1 receptor agonist: Novo Nordisk Prof. Francesco Giorgino declares the following: Grants/Research Support recipient: Eli Lilly, Roche Diabetes Care Consultant (Occasional): Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, Sanofi Honorarium recipient: Eli Lilly, Roche Diabetes Care, Boehringer Ingelheim, NovoNordisk, AstraZeneca, Sanofi, Mundipharma Funding statement: This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

In the the latest news episode, we bring you a 5-minute summary of the SUSTAIN FORTE results presented at ADA. This trial investigated whether once-weekly semaglutide 2mg was superior at reducing HbA1c in type 2 diabetes, compared with a 1mg dose. Listen for a quick overview of the key findings. Abstract: Frias J P, et al. Diabetes 2021 Jun; 70(Supplement 1) For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

While GLP-1 RAs and SGLT2is have a lot of data to support their cardio and renal protective effects, the precise mode of action for these effects remains unknown. Trials like EMPEROR-reduced, DAPA-HF and DAPA-CKD have shown that these effects, in the case of SGLT2is, are independent of diabetes status, and similar trials are ongoing in GLP-1 RAs. So what happens if we use both agents? Could this produce an additive cardioprotective effect, or might they cancel each other out? In this episode we discuss these questions with Dr Darren McGuire, Professor of Internal Medicine at the University of Texas Southwestern Medical Center in the Division of Cardiology, whose expertise is in large scale CVOTs and drug regulation in the field of diabetes and cardiology. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Dr. Darren McGuire declares the following: Clinical trial leadership: AstraZeneca, Boehringer Ingelheim, Eisai Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co. Inc, Novo Nordisk, Sanofi, CSL Behring Consultancy: Affimune, Applied Therapeautics, AstraZeneca, Boehringer Ingelheim, Lilly, Merck & Co. Inc, Pfizer Inc, Novo Nordisk, Metavant, Sanofi All conflicts of interest have been mitigated prior to this activity. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Following the last episode focusing on GLP-1 RAs, we are now turning to SLGT2 inhibitors. Which patients would benefit most from an SGLT2 inhibitor, and who should we avoid offering one? To help answer these questions, we're joined by Dr Kevin Fernando, GP Partner and Scottish Lead for the UK Primary Care Diabetes Society. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education. Disclosures: Dr Kevin Fernando declares the following: Advisory Board Member - Lilly, Napp, Boehringer Ingelheim Speaker Honorarium - Lilly, Napp, Boehringer Ingelheim References: - Zinman B et al. N Engl J Med. 2015;373(22):2117-2128 [EMPA-REG OUTCOME]. - Neal B et al. N Engl J Med. 2017;377(7):644-657 [CANVAS]. - Wiviott SD et al. N Engl J Med. 2019;380(4):347-357 [DECLARE-TIMI 58]. - Cannon CP et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435 [VERTIS-CV]. - Perkovic V et al. N Engl J Med. 2019;380(24):2295-2306 [CREDENCE]. - McGuire D et al. JAMA Cardiol. 2021; 6(2): 1–11 [CVOT meta-analysis]. - Heerspink H et al. N Engl J Med. 2020 Oct 8;383(15):1436-1446 [DAPA-CKD]. - Packer M et al. N Engl J Med. 2020 Oct 8;383(15):1413-1424 [EMPEROR-Reduced]. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp., and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

The GLP-1 receptor agonist class offers multifactorial benefits, including reductions in blood glucose, weight loss and cardiovascular protection. But do these vary across the class, and which patients should be offered one? And given they also carry a high risk of gastrointestinal side effects, how should we approach initiating therapy? Join us for a conversation with Prof. Carel Le Roux, Professor of Experimental Pathology and Co-Director of the Metabolic Medicine Group at University College Dublin, and Reader in Investigative Science at Imperial College London. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Carel Le Roux has been an advisory board member for Boehringer Ingelheim, Herbalife, GI Dynamics, Johnson & Johnson, and Novo Nordisk. References: Trujillo J et al. Ther Adv Endocrinol Metab. 2021 Mar;12 American Diabetes Association. Diabetes Care 2021; 44(Supplement 1) Buse J et al. Diabetes Care. 2020 Feb;43(2):487-493 Marso S et al. N Engl J Med. 2016 Jul 28;375(4):311-22 [LEADER] Marso S et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844 [SUSTAIN 6] Hernandez A et al. Lancet. 2018 Oct 27;392(10157):1519-1529 [Harmony Outcomes] Gerstein H et al. Lancet. 2019 Jul 13;394(10193):121-130 [REWIND] Husain M et al. N Engl J Med. 2019 Aug 29;381(9):841-851 [PIONEER 6] Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Multifactorial management is essential in diabetes and can often require multidisciplinary care. In order to help patients reduce their risk of kidney disease, or to help manage the condition of someone with a confirmed diagnosis, effective collaboration with nephrology colleagues is key. So how can diabetes and nephrology specialists best work together? Providing the perspective of a nephrology specialist is Professor Ian de Boer, Professor of Medicine and Associate Director of the Kidney Research Institute at the University of Washington in Seattle, and co-chair of the 2020 Diabetes in CKD Guideline published by Kidney Disease: Improving Global Outcomes or KDIGO. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Ian de Boer declares the following: Advisor: AstraZeneca, Bayer, Boehringer-Ingelheim Received equipment and supplies for research: DexCom Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp., and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Alex Edmans is a professor of finance at London Business School and the author of the book, "Grow the Pie: How Great Companies Deliver Both Purpose and Profit". He is an expert in corporate governance, executive compensation, corporate social responsibility, and behavioral finance. He has spoken at the World Economic Forum in Davos, at the World Bank Distinguished Speaker Series and in the UK House of Commons, and given multiple TED Talks. Alex graduated from Oxford University and then worked for Morgan Stanley in investment banking (London) and fixed income sales and trading (New York). After a PhD in Finance from MIT Sloan as a Fulbright Scholar, he joined Wharton in 2007 and was tenured in 2013 shortly before moving to LBS. Learn more about Alex at: alexedmans.com Timestamps: 0:00 - Introduction 05:51 - Laurie Hodrick's Influence on Alex 09:41 - What drives Alex as a Professor? 12:46 - Role of Technology in Dissemination of Knowledge 18:36 - About Alex's Book - Grow the Pie 21:10 - Addressing the Dilemma of Purpose vs Profits 24:23 - Short-term vs Long-term Value 29:13 - Grow the Pie Mentality for Individuals and Startups 32:25 - Using Metrics to get Feedback 37:10 - Can we rely on companies to stay committed? (Corporate Ethics) 45:18 - What does Alex's Utopia look like? Mentioned in the Podcast: 1) Laurie Simon Hodrick is a Visiting Professor of Law and Rock Center for Corporate Governance Fellow at Stanford Law School, a visiting fellow at the Hoover Institution at Stanford University, and the A. Barton Hepburn Professor Emerita of Economics in the Faculty of Business at Columbia Business School. 2) 10 Questions: www.ft.com/content/c5c386a8-64fb-11e0-9369-00144feab49a 3) Mathew Syed - Matthew Syed is an author and highly acclaimed speaker in the field of high performance. He has written six bestselling books on the subject of mindset and high performance – Rebel Ideas, Bounce, Black Box Thinking – and has worked with many leading organizations to build a mindset of continuous improvement. 4) Quantified Self Revolution - The Quantified Self is an international community of users and makers of self-tracking tools who share an interest in “self-knowledge through numbers." quantifiedself.com 5) Merck & Co., Inc - d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. 6) Unilever - Unilever is an Anglo-Dutch multinational consumer goods company headquartered in London, England, and Rotterdam, Netherlands. 7) Paul Polman - Paulus Polman is a Dutch businessman. He is a former Procter & Gamble president for Western Europe. In 2006 Polman joined Nestlé as chief financial officer and became vice president for the Americas in February 2008 8) Alan Jope - Alan Jope is a Scottish businessman, and the CEO of Unilever since January 2019, succeeding Paul Polman. 9) Roy Vagelos - Pindaros Roy Vagelos, better known as P. Roy Vagelos or Roy Vagelos, is an American physician and business executive, who was president and chief executive officer and chairman of the American pharmaceutical company Merck & Co. Since 1995, Vagelos has served as chairman of the board of Regeneron Pharmaceuticals. --- Send in a voice message: https://anchor.fm/utopia-is-now/message

Chronic kidney disease is a significant concern in diabetes. In this episode we discuss how best to manage the risk of developing or worsening of CKD, through factors such as blood pressure, blood lipids, lifestyle and the use of nephroprotective agents. We are joined by Dr David Cherney, whose research focuses on the development of renal disease in diabetes. Dr Cherney is Associate Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References: Thomas M. Adv Chronic Kidney Dis. 2014;21(3):311-7 Laiteerapong N et al. Diabetes Care. 2019; 42(3): 416–426. Duan J et al. Sci Rep. 2019; 9(1):10408 Kidney Disease Improving Global Outcomes. Kidney International. 2020 98, S1–S115 Cosentino F et al. Eur Heart J. 2020; 41(2):255-323 Heerspink H et al. N Engl J Med. 2020;383(15):1436-1446. American Diabetes Association. Diabetes Care 2021; 44(Supplement 1) Zelniker T et al. Circulation. 2019 ;139(17):2022-2031 Disclosures: Dr. David Cherney declares the following: Grants/research support: Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca and Novo-Nordisk Consulting, speaking honoraria: Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS and Novo-Nordisk Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

In the first of a series of special news episode, we bring you a 5-minute summary of the latest secondary analysis of EMPEROR-Reduced: the cardiovascular outcomes trial investigating the SGLT2 inhibitor empagliflozin in people with heart failure with reduced ejection fraction (HFrEF). This analysis investigated whether the effects of empagliflozin on cardiovascular outcomes varied according to baseline health status. Here we present a rapid summary of the key findings. Full publication: Butler J, et al. Eur Heart J. 2021 Apr 1; 42(13): 1203–1212. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education

Data show that GLP-1 RAs and SGLT2 inhibitors can reduce the risk of major adverse cardiovascular events (MACE) in people with type 2 diabetes with established risk factors. Given these therapies have multifactorial benefits, and that guideline advice has been shifting towards starting dual therapy earlier for many presentations, should we consider these agents for people who are not high risk? Prof. Steve Bain answers your questions This series will feature episodes aiming to address areas with unanswered clinical questions; first up we will be speaking to Prof. Stephen Bain about offering cardioprotective agents in type 2 diabetes. Send any questions to contact@knowledgeinpractice.eu or message us on Twitter/LinkedIn. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References: DECLARE-TIMI 58: Wiviott S, et al. N Engl J Med. 2019 Jan 24;380(4):347-357. REWIND: Gerstein H, et al. Lancet. 2019 Jul 13;394(10193):121-130.v CREDENCE: Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. VERIFY: Matthews D, et al. Lancet. 2019 Oct 26;394(10208):1519-1529. Buse J, et al. Diabetes Care. 2020;43(2):487-493 Cosentino F et al. Eur Heart J. 2020 Jan 7;41(2):255-323 Disclosures: Prof. Stephen Bain declares no relevant financial relationships Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Given that cardiovascular health is an area of major concern in diabetes, multidisciplinary care is essential to ensure that comprehensive and multifactorial management plans can be put in place. So how can diabetes specialists best work with those in cardiology? Today we’re joined by Professor Lars Rydén, to discuss collaboration opportunities for healthcare professionals in both diabetes and cardiology. Professor Rydén is Senior Professor of Cardiology at the Karolinska Institute in Stockholm and is a past president of the European Society of Cardiology. As well as focusing much of his research on cardiovascular disease in diabetes, he also chaired the Task Forces of the 2007 and 2013 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Do you have a question for our expert faculty? This series will feature episodes aiming to address areas with unanswered clinical questions; first up we will be speaking to Prof. Stephen Bain about offering cardioprotective agents in type 2 diabetes. Send any questions to contact@knowledgeinpractice.eu or message us on Twitter/LinkedIn. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Professor Lars Rydén declares no relevant financial relationships within the past 12 months. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

Merck Sharp & Dohme Corp. v. Albrecht | 01/07/19 | Docket #: 17-290

Merck Sharp & Dohme Corp. v. Albrecht